USPTO serial 79283585
RAFARM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MASON, JARED MICHAEL
- Law office
- TMO LAW OFFICE 119 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with RAFARM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Dental wax; dietary and nutritional supplements; dietetic foods adapted for medical use; disinfectant bathroom cleaners; disinfectant toilet bowl cleaners; disinfectants for chemical toilets; disinfectants for contact lenses; disinfectants for hygienic purposes; disinfectants for medical instruments; disinfectants for sanitary purposes; disinfecting handwash; fungicides; herbicides; herbicides for agricultural use; herbicides for domestic use; herbicides, insecticides, pesticides and fungicides for home, garden and lawn use and for professional use; material for stopping teeth; medical adhesive tape; medical adhesives for binding wounds; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for the treatment of iron deficiency; pharmaceutical preparations for the treatment and/or prevention of heart rhythm disorders; pharmaceutical preparations for the treatment and/or prevention of nausea and vomiting; pharmaceutical preparations for the treatment of allergies or allergy symptoms; pharmaceutical preparations for the treatment and/or prevention of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment and/or prevention of infectious diseases; pharmaceutical preparations for treating and/or preventing allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment and/or prevention of ocular hypertension or glaucoma; pharmaceutical preparations for the treatment and/or prevention of ocular inflammation or pain; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; otic preparations; ear drops; pharmaceutical products for ophthalmological use; pharmaceutical preparations for wounds; pharmaceutical preparations for kidney diseases; pharmaceutical preparations for the treatment of otic disorders; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, muscle relaxants; pharmaceutical preparations, namely, corticosteroids; pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations, namely, anti-infectives; pharmaceutical preparations, namely, anti-bacterials; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, antivirals; pharmaceutical preparations, namely, immunosuppresants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; preparations for destroying parasites; preparations for destroying vermin; sanitary preparations for medical use; self adhesive dressings; veterinary preparations, namely, pain relief medication; medicinal preparations for the treatment of infectious diseases and for use in oncology; antiallergic medicines; medicines for the treatment of gastrointestinal disorders | ACTIVE | — |
| 035 | Advertising; management of the business affairs and commercial functions in the field of pharmaceuticals; business development services in the field of pharmaceuticals; business management; business administration | ACTIVE | — |
| 042 | Pharmaceutical drug development services; pharmaceutical research services; scientific investigations for medical purposes in the field of pharmaceuticals; scientific research in the field of pharmaceuticals; scientific research and development in the field of pharmaceuticals; scientific research and development of new pharmaceutical products for others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 5, 2021 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 18, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 18, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 10, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 22, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 22, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 18, 2020 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 18, 2020 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 23, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 7, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 7, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 24, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 24, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 23, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 20, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 20, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 16, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |